Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

I multiple-dose HCV trial were presented that showed bavituximab was well tolerated and demonstrated encouraging signs of anti-viral activity.

Cotara(R) Brain Cancer Clinical Program

To help accelerate the ongoing Phase II trial of Cotara in patients with glioblastoma multiforme, one of the most deadly forms of brain cancer, Peregrine recently added two new sites to the study, for a total of seven clinical sites now actively screening and recruiting patients. In addition, Peregrine regained operational responsibility for the ongoing Cotara dosimetry and dose confirmation clinical study and is working closely with the participating academic medical centers to complete patient enrollment and dosing during 2008. Positive results from these two clinical trials are expected to pave the way for Phase III product registration trials for Cotara.

Mr. King concluded, "In 2008 we plan to conduct a number of mid-phase trials for our lead clinical programs, each of which has significant clinical and commercial potential. We have long maintained that positive Phase II clinical data would be the keys to building sustainable shareholder value in the company, and we are optimistic that Peregrine will be able to begin delivering on that promise in the upcoming year."

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional informatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...BEIJING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Yon... or "the Company") a leading manufacturer, develop...animal nutrient products in the,People,s Republic ...ct a,conference call at 10:00 a.m. Eastern Time (1...09 to discuss results for the quarter ended Septem...
(Date:11/9/2009)...DIEGO, Nov. 9 NexBio, Inc. announc... American College of Allergy, Asthma, and Immunolo...ed "DAS181 (Fludase®), a Sialidase, Decreases...y Effects in Animal Models of Asthma". ,, DAS18...ectrum host-targeting drug candidate being studied...
(Date:11/9/2009)...LONDON, November 9 Following the p... Food and Drug Administration (FDA), privately,own.../www.davalinternational.com ) has been informed th...R) has been awarded an Orphan-Drug,designation for...LS). , ALS, also known as Lou Gehrig,s di...
(Date:11/6/2009)...NTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Bios...t has re-filed the Form 52-109F1 Certification of ...ive Officer and James Long, the Chief Financial Of... 12, 2009 in connection with the annual audited fi..., 2008. ,, The Company initially filed the annu...
Breaking Biology Technology:Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3
...ct. 4 Vicus Therapeutics, LLC, an,oncology-focuse...y,announced that John Maki, President and Chief Ex...cussions titled "Outsourcing: Best Practices,and L...Exit Strategies:,Managing Risk and Reward" at BIOT...will run from 9:00 a.m. to 10:15 a.m. ET and from ...
...Newswire-FirstCall/ - Ms. Mary Ann Dillahunty, Vic...iotech Inc. (TSX: ONC,NASDAQ: ONCY), will present ...rForum 2007 on Thursday, October 11 at 12 p.m. PT....n San Francisco from October 9-11, 2007. A live a... on the,company,s website at http://www.oncolytic...
...lude the Recently Released Strong Results from the...pyScore Human Appendicitis Blood... Oct. 4 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ...he,development of novel drugs and diagnostics for ... the Edgewater Research Investor Conference, sched...
Other Biology Technology:Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels 2Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007 2AspenBio Pharma to Present the Edgewater Research Investor Conference 2
(Date:11/8/2009)... , HEALTH EDUCATION DESIGNED FOR ADULTS WITH IN...IER LIVES , An Indiana University study involvi...t the adults increased their personal health knowl...ks. , Adults with ID, an internationally accept...er rates of obesity, physical inactivity and preve...
(Date:11/6/2009)... To celebrate the 150th anniversary this month of...American Institute of Biological Sciences (AIBS) i...s about Charles Darwin and his historic insights i...dian of the University of California, Berkeley, an...adian,s article, "Ten Myths About Charles Darwin,"...
(Date:11/6/2009)...,, DETROIT, Nov. 6 Auburn Hills...C (LEID) will be installing its locker system and ... (BACS) at the U.S. Department of Health and Human...ed in Bethesda, MD. The locker system will suppor...e for protecting our nation,s medical research age...
Breaking Biology News(10 mins):Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 1US Oncology Inc Announces 24465 Million Senior Secured Notes Offering 47879 2Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 1Xceed Meets HTX CIHR Grant Milestone 3A Decreasing Sample Prep Time From Days to Less Than Eight Hours 12464 2MPR Drug Database Available as a Free Download for Mobile Devices Including BlackBerry and Palm 47875 1MPR Drug Database Available as a Free Download for Mobile Devices Including BlackBerry and Palm 47875 2
...etic Investigation of Anthropometric Parameters) c... So far, the scientists have analyzed two million ...es with a total of more than 32,000 participants. ...ed in 14 further studies including 59,000 particip...y known, it was now possible for six more obesity ...
...w race cars to take tight turns at high speeds. Hi...ages: They are not necessary for basic flight but ...dators. , "To escape a predator, you don,t have to...Tom Eisner, a world authority on animal behavior, ... Professor Emeritus of Chemical Ecology at Cornell...
... 7 WCC Smart Search & Match, the,leading prov..., today,announced that Tarvinder Sembhi has joined... market. , Mr. Sembhi is a veteran executive i...s most recently President of 4G Identity Solutions...evelopment, corporate branding and,marketing, and ...
Other Biology News:Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect 2Hind wings help butterflies make swift turns to evade predators, study finds 2
Chicken Anti-Human AP2M1 Antibody, Unconjugated from ABR-Affinity BioReagents
Human Flt-3/Flk-2 Ligand from eBioscience
Rabbit Anti-GJB2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-IKKbeta / IKK-2 Polyclonal Antibody, Unconjugated from BioVision
Biology Products: